A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial.
Snydman
D R
DR
Department of Medicine, New England Medical Center, Boston, MA 02111.
Werner
B G
BG
Tilney
N L
NL
Kirkman
R L
RL
Milford
E L
EL
Cho
S I
SI
Bush
H L
HL
Levey
A S
AS
Strom
T B
TB
Carpenter
C B
CB
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000009:adverse effects; D007116:Immunization, Passive; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000209:etiology; D011446:Prospective Studies; D011897:Random Allocation; D013577:Syndrome
D007106:Immune Sera; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; C045781:cytomegalovirus-specific hyperimmune globulin